JP2007502855A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007502855A5 JP2007502855A5 JP2006530541A JP2006530541A JP2007502855A5 JP 2007502855 A5 JP2007502855 A5 JP 2007502855A5 JP 2006530541 A JP2006530541 A JP 2006530541A JP 2006530541 A JP2006530541 A JP 2006530541A JP 2007502855 A5 JP2007502855 A5 JP 2007502855A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- derivative
- disease
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0312292.6 | 2003-05-29 | ||
| GB0312292A GB0312292D0 (en) | 2003-05-29 | 2003-05-29 | Treatment of blood vessels |
| GB0400547.6 | 2004-01-12 | ||
| GB0400547A GB0400547D0 (en) | 2004-01-12 | 2004-01-12 | Treatment of blood vessels |
| PCT/GB2004/002269 WO2004105784A1 (en) | 2003-05-29 | 2004-05-28 | Class iii slrp agonists for the reduction of blood vessel formation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007502855A JP2007502855A (ja) | 2007-02-15 |
| JP2007502855A5 true JP2007502855A5 (enExample) | 2007-07-12 |
| JP4808623B2 JP4808623B2 (ja) | 2011-11-02 |
Family
ID=33492244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006530541A Expired - Fee Related JP4808623B2 (ja) | 2003-05-29 | 2004-05-28 | 血管形成を減少させるためのクラスｉｉｉのｓｌｒｐのアゴニスト |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7358224B2 (enExample) |
| EP (1) | EP1638591B1 (enExample) |
| JP (1) | JP4808623B2 (enExample) |
| DK (1) | DK1638591T3 (enExample) |
| ES (1) | ES2408656T3 (enExample) |
| PL (1) | PL1638591T3 (enExample) |
| PT (1) | PT1638591E (enExample) |
| WO (1) | WO2004105784A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004105784A1 (en) | 2003-05-29 | 2004-12-09 | The University Of Manchester | Class iii slrp agonists for the reduction of blood vessel formation |
| GB0423273D0 (en) * | 2004-10-20 | 2004-11-24 | Univ Manchester | Treatment of cancer |
| GB0724832D0 (en) * | 2007-12-20 | 2008-01-30 | Univ Manchester | Proteins and nucleic acids |
| CN102549436A (zh) | 2009-07-27 | 2012-07-04 | 霍夫曼-拉罗奇有限公司 | mimecan在评价心力衰竭中的用途 |
| CA2781309A1 (en) * | 2009-12-04 | 2011-06-09 | Euclid Systems Corporation | Composition and methods for the prevention and treatment of macular degeneration, diabetic retinopathy, and diabetic macular edema |
| CN102188694B (zh) * | 2010-03-11 | 2015-05-06 | 上海交通大学医学院附属瑞金医院 | 骨生成诱导因子的用途 |
| EP3115784A1 (en) * | 2015-07-10 | 2017-01-11 | Koss, Michael Janusz | Polypeptide marker for analysis, diagnosis and therapy of eye-related diseases |
| US20180369325A1 (en) * | 2015-11-19 | 2018-12-27 | Garvan Institute Of Medical Research | Compounds and methods for treating metabolic disorders |
| AU2024305223A1 (en) * | 2023-06-13 | 2025-12-18 | Rijksuniversiteit Groningen | Osteoglycin as regenerative agent for lung tissue |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5827702A (en) * | 1994-10-31 | 1998-10-27 | Genentech, Inc. | Ocular gene therapy |
| DE4445630A1 (de) | 1994-12-21 | 1996-06-27 | Forssmann Wolf Georg | Humane zirkulierende Peptidfragmente 20-92 und 23-74 des Precursor des Osteoinduktiven Faktors kurz: OIF-20-92 und OIF 23-74 |
| CA2235685A1 (en) | 1995-10-23 | 1997-05-01 | Hyal Pharmaceutical Australia Limited | Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization |
| ATE343400T1 (de) | 1996-09-24 | 2006-11-15 | Merck & Co Inc | Verbindungen zur hemmung der angiogenese durch gentherapie |
| AU5593398A (en) * | 1996-12-05 | 1998-06-29 | Alcon Laboratories, Inc. | The use of inhibitors of tgf-beta's functions to ameliorate ocular pathology |
| WO2000068264A2 (en) * | 1999-05-10 | 2000-11-16 | The Texas A & M University System | A peptide inhibitor of fibrinogen blood clotting |
| DE60043736D1 (de) * | 1999-09-15 | 2010-03-11 | Euclid Systems Corp | Zusammensetzung zur stabilisierung des corneagewebon kontaktlinsen |
| JP2003511012A (ja) * | 1999-09-24 | 2003-03-25 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ３２個のヒト分泌タンパク質 |
| US7304137B2 (en) * | 2001-12-13 | 2007-12-04 | The Texas A & M University System | Nucleotide and amino acid sequences of asporins |
| WO2004105784A1 (en) | 2003-05-29 | 2004-12-09 | The University Of Manchester | Class iii slrp agonists for the reduction of blood vessel formation |
| GB0423273D0 (en) * | 2004-10-20 | 2004-11-24 | Univ Manchester | Treatment of cancer |
-
2004
- 2004-05-28 WO PCT/GB2004/002269 patent/WO2004105784A1/en not_active Ceased
- 2004-05-28 PT PT47352596T patent/PT1638591E/pt unknown
- 2004-05-28 EP EP04735259A patent/EP1638591B1/en not_active Expired - Lifetime
- 2004-05-28 DK DK04735259.6T patent/DK1638591T3/da active
- 2004-05-28 JP JP2006530541A patent/JP4808623B2/ja not_active Expired - Fee Related
- 2004-05-28 US US10/558,606 patent/US7358224B2/en not_active Expired - Fee Related
- 2004-05-28 PL PL04735259T patent/PL1638591T3/pl unknown
- 2004-05-28 ES ES04735259T patent/ES2408656T3/es not_active Expired - Lifetime
-
2008
- 2008-04-11 US US12/101,717 patent/US7910567B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018250312C1 (en) | Bioorthogonal compositions | |
| Des Rieux et al. | 3D systems delivering VEGF to promote angiogenesis for tissue engineering | |
| JP5739908B2 (ja) | 血管形成関連の眼疾患の処置のための組成物および方法 | |
| AU2016350613A1 (en) | Conditionally active polypeptides | |
| JP2007502855A5 (enExample) | ||
| CN114081951A (zh) | 治疗眼病的方法 | |
| JP2015524444A5 (enExample) | ||
| JP2007509984A5 (enExample) | ||
| CY1108932T1 (el) | Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων | |
| ATE470443T1 (de) | Indol-1-yl-essigsäurederivate | |
| Robert et al. | A drug delivery system for administration of anti–TNF-α antibody | |
| ES2681195T3 (es) | Utilización de la proteína de fusión TACI-Ig, tal como atacicept, para la fabricación de un medicamento para el tratamiento de lupus eritematoso | |
| MY144897A (en) | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists | |
| Zheng et al. | Inhibition of ocular neovascularization by a novel peptide derived from human placenta growth factor‐1 | |
| US20240123042A1 (en) | Methods and compositions related to a tissue factor-targeting igg3 immunoconjugates | |
| JP2010537623A5 (enExample) | ||
| Lukovic et al. | Human recombinant activated protein C-coated stent for the prevention of restenosis in porcine coronary arteries | |
| JP2025509568A (ja) | 新生血管加齢性黄斑変性を治療する方法 | |
| JP2018534306A5 (enExample) | ||
| Cai et al. | Recent developments in targeting bromodomain and extra terminal domain proteins for cancer therapeutics | |
| Lino et al. | Small extracellular vesicles administered directly in the brain promote neuroprotection and decreased microglia reactivity in a stroke mouse model | |
| US20210137953A1 (en) | Inhibitors of Mcl-1 and Akt Binding, Pharmaceutical Compositions, and Uses in Treating Cancer | |
| Shin et al. | A rat tracheal model to investigate stent-induced tissue hyperplasia: a pilot study | |
| JP2008517045A5 (enExample) | ||
| WO2016205459A3 (en) | Therapeutic nanofiber hydrogels for local treatment of brain-related diseases |